Literature DB >> 17526675

Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis.

Harry R Gosker1, Maurice P Zeegers, Emiel F M Wouters, Annemie M W J Schols.   

Abstract

BACKGROUND: Skeletal muscle dysfunction is a common feature in chronic obstructive pulmonary disease (COPD) which is associated with intrinsic muscular abnormalities. One of the most consistently reported alterations is a shift from fibre type I to II in the vastus lateralis of these patients. Surprisingly, the relationship between this shift and the severity and phenotype of COPD remains unclear. A study was conducted to determine whether vastus lateralis muscle fibre type proportions are associated with COPD disease severity and to provide reference values for the proportions of fibre types in the vastus lateralis in COPD.
METHODS: A systematic review and a meta-analysis were conducted in which muscle fibre type data and markers of disease severity were collected from the literature.
RESULTS: The forced expiratory volume in 1 s (FEV(1)), the ratio of FEV(1) to forced vital capacity (FVC) and body mass index were positively associated with the proportion of type I fibres in COPD. A proportion of 51% for vastus lateralis fibre type I and 13% for fibre type IIX were calculated from the combined data as normal values for patients with typical GOLD stage 3-4 COPD aged 60-70 years. Based on these reference values, a proportion of fibre type I <27% and of fibre type IIX >29% were defined as pathologically abnormal.
CONCLUSIONS: This review sheds new light on the relationship between skeletal muscle abnormalities and important hallmarks of the disease in severe COPD, and identifies absence of data in GOLD stages 1-2. This review also provides reference values on fibre type composition for diagnostic purposes in COPD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17526675      PMCID: PMC2117111          DOI: 10.1136/thx.2007.078980

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  35 in total

1.  [Changes in exercise tolerance, health related quality of life, and peripheral muscle characteristics of chronic obstructive pulmonary disease patients after 6 weeks' training].

Authors:  M Montes de Oca; S H Torres; Y González; E Romero; N Hernández; C Tálamo
Journal:  Arch Bronconeumol       Date:  2005-08       Impact factor: 4.872

2.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary updated 2003.

Authors:  Leonardo Fabbri; Romain A Pauwels; Suzanne S Hurd
Journal:  COPD       Date:  2004-04       Impact factor: 2.409

3.  Hypoxaemia enhances peripheral muscle oxidative stress in chronic obstructive pulmonary disease.

Authors:  C Koechlin; F Maltais; D Saey; A Michaud; P LeBlanc; M Hayot; C Préfaut
Journal:  Thorax       Date:  2005-06-17       Impact factor: 9.139

4.  Body composition and mortality in chronic obstructive pulmonary disease.

Authors:  Annemie M W J Schols; Roelinka Broekhuizen; Clarie A Weling-Scheepers; Emiel F Wouters
Journal:  Am J Clin Nutr       Date:  2005-07       Impact factor: 7.045

5.  Contractile fatigue, muscle morphometry, and blood lactate in chronic obstructive pulmonary disease.

Authors:  Didier Saey; Annie Michaud; Annabelle Couillard; Claude H Côté; M Jeffery Mador; Pierre LeBlanc; Jean Jobin; François Maltais
Journal:  Am J Respir Crit Care Med       Date:  2005-02-25       Impact factor: 21.405

6.  Exercise training restores uncoupling protein-3 content in limb muscles of patients with chronic obstructive pulmonary disease.

Authors:  Harry R Gosker; Patrick Schrauwen; Roelinka Broekhuizen; Matthijs K C Hesselink; Esther Moonen-Kornips; Kimberly A Ward; Frits M E Franssen; Emiel F M Wouters; Annemie M W J Schols
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-12-13       Impact factor: 4.310

7.  Skeletal muscle adaptations to interval training in patients with advanced COPD.

Authors:  Ioannis Vogiatzis; Gerasimos Terzis; Serafeim Nanas; Grigoris Stratakos; Davina C M Simoes; Olga Georgiadou; Spyros Zakynthinos; Charis Roussos
Journal:  Chest       Date:  2005-12       Impact factor: 9.410

8.  COPD results in a reduction in UCP3 long mRNA and UCP3 protein content in types I and IIa skeletal muscle fibers.

Authors:  Aaron P Russell; Emmanuel Somm; Richard Debigaré; Oliver Hartley; Denis Richard; Giacomo Gastaldi; Astrid Melotti; Annie Michaud; Jean-Paul Giacobino; Patrick Muzzin; Pierre LeBlanc; François Maltais
Journal:  J Cardiopulm Rehabil       Date:  2004 Sep-Oct       Impact factor: 2.081

9.  Adaptation of the diaphragm and the vastus lateralis in mild-to-moderate COPD.

Authors:  M Doucet; R Debigaré; D R Joanisse; C Côté; P Leblanc; J Grégoire; J Deslauriers; R Vaillancourt; F Maltais
Journal:  Eur Respir J       Date:  2004-12       Impact factor: 16.671

10.  Peripheral muscle composition and health status in patients with COPD.

Authors:  María Montes de Oca; Sonia H Torres; Yudith Gonzalez; Elizabeth Romero; Noelina Hernández; Abdón Mata; Carlos Tálamo
Journal:  Respir Med       Date:  2006-03-20       Impact factor: 3.415

View more
  69 in total

Review 1.  Molecular and biological pathways of skeletal muscle dysfunction in chronic obstructive pulmonary disease.

Authors:  Esther Barreiro; Joaquim Gea
Journal:  Chron Respir Dis       Date:  2016-04-06       Impact factor: 2.444

2.  Is age-related decline in lean mass and physical function accelerated by obstructive lung disease or smoking?

Authors:  Bram van den Borst; Annemarie Koster; Binbing Yu; Harry R Gosker; Bernd Meibohm; Douglas C Bauer; Stephen B Kritchevsky; Yongmei Liu; Anne B Newman; Tamara B Harris; Annemie M W J Schols
Journal:  Thorax       Date:  2011-07-01       Impact factor: 9.139

3.  Sex differences in function and structure of the quadriceps muscle in chronic obstructive pulmonary disease patients.

Authors:  Pilar Ausín; Juana Martínez-Llorens; Marina Sabaté-Bresco; Carme Casadevall; Esther Barreiro; Joaquim Gea
Journal:  Chron Respir Dis       Date:  2016-12-06       Impact factor: 2.444

4.  High oxygen extraction and slow recovery of muscle deoxygenation kinetics after neuromuscular electrical stimulation in COPD patients.

Authors:  Diego de Paiva Azevedo; Wladimir Musetti Medeiros; Flávia Fernandes Manfredi de Freitas; Cesar Ferreira Amorim; Ana Cristina Oliveira Gimenes; Jose Alberto Neder; Luciana Dias Chiavegato
Journal:  Eur J Appl Physiol       Date:  2016-07-28       Impact factor: 3.078

5.  Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease. What We Know and Can Do for Our Patients.

Authors:  Ariel Jaitovich; Esther Barreiro
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

6.  Exposure to cigarette smoke induces overexpression of von Hippel-Lindau tumor suppressor in mouse skeletal muscle.

Authors:  Vladimir T Basic; Elsa Tadele; Ali Ateia Elmabsout; Hongwei Yao; Irfan Rahman; Allan Sirsjö; Samy M Abdel-Halim
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-07-27       Impact factor: 5.464

Review 7.  Skeletal muscle fiber type: using insights from muscle developmental biology to dissect targets for susceptibility and resistance to muscle disease.

Authors:  Jared Talbot; Lisa Maves
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2016-05-19       Impact factor: 5.814

8.  Quadriceps muscle strength in scoliosis.

Authors:  E B Swallow; E Barreiro; H Gosker; S A Sathyapala; F Sanchez; N S Hopkinson; J Moxham; A Schols; J Gea; M I Polkey
Journal:  Eur Respir J       Date:  2009-05-14       Impact factor: 16.671

9.  Diabetes, muscles, and the myth of Ulysses' bow.

Authors:  Luigi Ferrucci; Stephanie Studenski
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

10.  Cellular assessment of muscle in COPD: case studies of two males.

Authors:  Howard J Green; Eric Bombardier; Margaret E Burnett; Christine L D'Arsigny; Sobia Iqbal; Katherine A Webb; Jing Ouyang; Denis E O'Donnell
Journal:  Int J Gen Med       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.